… Patients classified as users of ICS at cohort entry were exposed to ICS … exposed to ICS for
6% of the days in the first year, increasing to 23% by year 5. Such misclassification of exposure …

… Inhaled corticosteroids (ICS) are now very widely used in high doses in the … of COPD
patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in COPD …

… If we admit a linear bone loss in glucocorticoid-induced osteoporosis, a patient exposed to …
% decrease in BMD compared with unexposed asthma or COPD control, whereas the related …

… Both systemic and inhaled corticosteroids may increase the … chronic obstructive pulmonary
disease (COPD) and asthma. … and corticosteroid exposure in patients with asthma and COPD. …

… study participants with a diagnosis of asthma or COPD (mean age, 80.6 years). We determined
the dose-response relationship between inhaled corticosteroid exposure and time to first …

… Inhaled corticosteroids (ICSs) are a mainstay of COPD … of pulmonary function decline in
COPD, despite improvements in … or a history of asthma or asthma–COPD overlap, may define a …

… Example of calculation of inhaled corticosteroid exposure during a 90-day interval. This
patient would be classified as an inhaled corticosteroid user during this interval because the …

… Since both tuberculosis and COPD due to exposure to biomass smoke are highly
prevalent in developing countries, there is an urgent need to perform interventional and/or …

… , nutritional deficiencies, low BMI, and exposure to corticosteroids. Treatment with ICS has
been recommended in selected patients with COPD. However, overprescription of ICSs is a …

… is life‐long so the period of these studies is small compared to the potential period of exposure
to inhaled corticosteroids. Second, the studies have been carried out in relatively low‐risk …